Navigation Links
Late-stage ovarian cancer shows promise in 2-drug phase I trial
Date:6/10/2010

INDIANAPOLIS -- The combination of decitabine and carboplatin appears to improve the outcome of women who have late-stage ovarian cancer. In an upcoming issue of the journal Cancer (online today), Indiana University researchers report four of 10 patients who participated in a phase I clinical trial had no disease progression after six months of treatment. One patient experienced complete resolution of tumor tissue for a period of time.

Advanced ovarian cancer is often diagnosed too late for treatment to be effective. Patients are often told they have virtually no chance of recovery and only months to live.

Women participating in the study were between 51 and 71, and had previously exhausted all approved treatments for ovarian cancer. They enrolled in an Indiana University Melvin and Bren Simon Cancer Center clinical trial designed to increase their sensitivity to the commonly prescribed ovarian cancer drug, platinum-based carboplatin.

Women with ovarian cancer usually survive less than one year after they become resistant to carboplatin and their cancer recurs, said co-principal investigator Daniela Matei, M.D., an associate professor of medicine at the Indiana University School of Medicine. Matei led the clinical portion of the trial.

"Carboplatin is the most efficient drug therapy for ovarian cancer," Matei said. "Unfortunately, patients with recurrent disease become resistant to the drug after one or two rounds."

Decitabine was first used to treat the study patients intravenously daily for five days followed on the eighth day with carboplatin. After a month, the regimen begins again.

Six months after the trial began, four of the patients had no disease progression. At eight-and-a-half months, seven patients were alive (and at press time, still alive). Cancerous tissue in one of the patients shrank completely.

Adverse reactions to the treatment regiments were mild, including nausea, fatigu
'/>"/>

Contact: Mary L. Hardin
mhardin@iupui.edu
317-274-7722
Indiana University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Late-stage ovarian cancer shows promise in two-drug phase I trial
2. Cancer Drug Safe for Late-Stage Pelvic Disease
3. Late-stage melanoma results in economic burden
4. New treatment regimen shown effective against advanced ovarian cancer
5. Early Detection of Ovarian Cancer Moves Closer
6. CA-125 change over time shows promise as screening tool for early detection of ovarian cancer
7. PMH cancer researchers link ovarian hormone to breast stem cells growth
8. Study Makes Strides in Understanding Ovarian Cancer
9. Researchers identify a new breast and ovarian cancer susceptibility gene
10. Ovarian cancer study offers vital clues for new therapies
11. Only women with Western Swedish breast cancer gene run higher risk of ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2015)... For people who are keen on the ... Market Research Report would be an useful report to ... the present market scenario of this industry. The report ... market of this industry. The report summarizes key statistics ... manufacturers in this industry. The report is a valuable ...
(Date:5/24/2015)... May 24, 2015 ProPin is a ... Cut Pro X. Utilize ProPin to pin point locations on ... scene. , ProPin allows users to choose from 30 ... FCPX. With on-screen controls, video editors can easily manipulate ProPin ... pin and mark with absolute ease. , Using ProPin is easy, ...
(Date:5/23/2015)... City, FL (PRWEB) May 23, 2015 On ... to build a new playground for Branches Florida City exactly ... the former play space in 2010. , A large fire ... new playground on May 23, 2010 in the middle of ... watched. The fire was later declared arson even though it ...
(Date:5/23/2015)... On May 16, the team at Farrell’s eXtreme ... mud obstacle run that raised funds for multiple sclerosis. ... the reason we participated was to support people living with ... eXtreme Bodyshaping. “One-hundred percent of the funds raised go to ... not only attended by eXtreme Bodyshaping staff, but members of ...
(Date:5/23/2015)... (PRWEB) May 23, 2015 Injury lawyer Steven ... has been passed by the Maryland legislature but which has ... Maryland General Assembly passed HB 449 with overwhelming ... has not signed it into law. This bill ensures that ... is growing that demonstrates the danger of fracking to our ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4Health News:Developers at Pixel Film Studios Release ProPin for Final Cut Pro X. 2Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3
... (BRONX, NY) Older women with hypertension are at ... later in life, according to data from the Women,s ... in the December 2009 online issue of the ... conducted as part of the Women,s Health Initiative (WHI), ...
... stem cell transplantation can extend "event-free survival" for breast ... breast cancer with and without distant metastases. However, there ... can more frequently give rise to severe complications affecting ... the final report of the Institute for Quality and ...
... in Vision and Ophthalmology is honored to announce this ... Fellow recognizes members for their accomplishments, leadership and contributions ... ARVO anticipates that Fellows will continue to serve as ... vision and ophthalmology research and to further ARVO,s vision ...
... , MOUNTAIN VIEW, Calif. , Jan. 12 ... a leading provider of medication system solutions to acute healthcare facilities, ... as its primary vendor for automated medication management solutions. , "To ... need a system that can account for and monitor medications from ...
... Jan. 12 United American Healthcare Corporation (Nasdaq: UAHC ... for the Company,s Annual Meeting of Shareholders as well as the record ... Annual Shareholders, Meeting will be held on Friday, April 23, 2010 ... 1777 Third Street in Detroit .  Shareholders of record as of ...
... government took big steps to stem smoking, while most states ... U.S. government took some important steps last year to prevent ... grade and 10 made alarming cuts to their tobacco control ... Tobacco Control 2009 report, released Tuesday by the American ...
Cached Medicine News:Health News:Hypertension linked to dementia in older women 2Health News:Hypertension linked to dementia in older women 3Health News:Women with breast cancer may benefit from autologous stem cell transplantation 2Health News:Women with breast cancer may benefit from autologous stem cell transplantation 3Health News:Women with breast cancer may benefit from autologous stem cell transplantation 4Health News:ARVO announces 2010 fellows 2Health News:ARVO announces 2010 fellows 3Health News:ARVO announces 2010 fellows 4Health News:NewYork-Presbyterian Hospital Selects Omnicell for Medication Management 2Health News:NewYork-Presbyterian Hospital Selects Omnicell for Medication Management 3Health News:NewYork-Presbyterian Hospital Selects Omnicell for Medication Management 4Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 2Health News:United American Healthcare Corporation Announces Meeting Date and Record Date for Annual Meeting of Shareholders 3Health News:Report Card on Tobacco Control Laws a Mixed Bag 2Health News:Report Card on Tobacco Control Laws a Mixed Bag 3Health News:Report Card on Tobacco Control Laws a Mixed Bag 4
(Date:5/22/2015)... Fla. , May 22, 2015 ... Heart Institute recently traveled to Boston, ... procedure at the 2015 Heart Rhythm Society conference. ... together to focus on the ideas, people and ... Convergent is a hybrid, minimally invasive cardiac ...
(Date:5/22/2015)... May 22, 2015  The U.S. Food and ... -- the first biosimilar product approved in ... toward growth in the contract manufacturing organization (CMO) ... industry is geared to the production of small-molecular ... biopharmaceutical products. The healthcare market research publisher,s report, ...
(Date:5/22/2015)... , May 22, 2015 ... Assay Market by Product (Consumables, Instruments, Services), by Test ... (ELISA, Chromatography, Flow Cytometry), by End Users - Global ... Assays Market is expected to reach $736.85 Million by ... CAGR of 10.25%. Browse 71 market ...
Breaking Medicine Technology:St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 2St. Joseph's Hospital Heart Institute Physician Presents at Heart Rhythm Society 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4
... USHIFU, LLC, a global leader in,non invasive high ... sponsorship of the Sonablate(R) International HIFU Registry,(SIHR), along ... and Takai,Hospital Supply Co., Ltd., (THS). The SIHR ... information about prostate cancer treatment using HIFU.,It was ...
... Benefits All Americans, WASHINGTON, July 9 In ... M.D., discussed the,safety and importance of the research programs ... as an absolute commitment to its patients,while expressing regret ... misused., "VA has an outstanding research program, and ...
Cached Medicine Technology:Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 2Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments 3Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 3
LB Agar plates with 0.1mM EDTA....
Luria bertani broth: 1.0% Tryptone, 0.5% Yeast Extract, 1.0% Sodium Chloride....
2.5% Soytone, 4.8% Yeast Extract, 0.025% Magnesium Sulfate, 130mM Calcium Chloride....
12% Tryptone, 24% Yeast Extract, 4.0% Glycerol. Supplied with 1 liter of 10x phosphate buffer (0190-1L)....
Medicine Products: